You are wrong. They were already finishing up on the remaining months of FAME that the FDA requested when they were told to submit that additional data (as well as fix their supplier problems). They made that submittable and then the latest CRL required 2 more studies which ALIM has not started nor will they at $75KK and 2 years of waiting!!
I am holding 30,000 shares waiting for a buyout by a big Pharma. Europe now and FDA in 2-3 years with a big Pharma footing the bill.
Alimera plans to meet with the U.S. Food and Drug Administration (FDA) during the second quarter of 2012 to discuss the complete response letter it received in November 2011 from the FDA in response to Alimera's New Drug Application for ILUVIEN for the treatment of DME associated with diabetic retinopathy.
PLus, "We expect to receive marketing authorization in each country by the end of the first quarter."